secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2021-09-10T23:59:59+00:00
Accession:  0001628280-21-018381
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals promotes Mary DiBiase to COO effective Sep 8, 2021
---------------------------------------------------------------------

- Dr. DiBiase previously SVP of Technical Operations & Quality; now oversees program/alliance mgmt and IT.
- Annual base salary $409,500; eligible for annual cash incentive at 40% of base salary target.
- Granted 27,000 RSUs vesting equally over three years.
- Severance terms include 12-month base salary continuation and accelerated equity vesting on qualifying termination.
- Promotion supports late-stage development of mavorixafor and preparations for potential commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/0001628280-21-018381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/xfor-20210910.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-018381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer